Filing Details

Accession Number:
0001104659-20-103494
Form Type:
4
Zero Holdings:
No
Publication Time:
2020-09-09 17:04:15
Reporting Period:
2020-09-04
Accepted Time:
2020-09-09 17:04:15
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1771917 Karuna Therapeutics Inc. KRTX () 4
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1245624 James Healy Sofinnova Investments, Inc.,
3000 Sand Hill Road, 4-250
Menlo Park CA 94025
Yes No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2020-09-04 1,670 $70.12 1,887,272 No 4 P Indirect By Sofinnova Venture Partners X, L.P.
Common Stock Acquisiton 2020-09-04 45,317 $71.30 1,932,589 No 4 P Indirect By Sofinnova Venture Partners X, L.P.
Common Stock Acquisiton 2020-09-04 6,461 $72.73 1,939,050 No 4 P Indirect By Sofinnova Venture Partners X, L.P.
Common Stock Acquisiton 2020-09-04 8,330 $73.59 1,947,380 No 4 P Indirect By Sofinnova Venture Partners X, L.P.
Common Stock Acquisiton 2020-09-08 504 $73.00 1,947,884 No 4 P Indirect By Sofinnova Venture Partners X, L.P.
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 P Indirect By Sofinnova Venture Partners X, L.P.
No 4 P Indirect By Sofinnova Venture Partners X, L.P.
No 4 P Indirect By Sofinnova Venture Partners X, L.P.
No 4 P Indirect By Sofinnova Venture Partners X, L.P.
No 4 P Indirect By Sofinnova Venture Partners X, L.P.
Footnotes
  1. The price reported in Column 4 is a weighted average price. These shares were acquired in multiple transactions at prices ranging from $69.66 to $70.61, inclusive. The reporting person undertakes to provide to Karuna Therapeutics, Inc., any security holder of Karuna Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the ranges set forth in this footnote (1) to this Form 4.
  2. All shares held by Sofinnova Venture Partners X, L.P. ("SVP X"). Sofinnova Management X, L.L.C. ("SM X"), the general partner of SVP X, may be deemed to have sole voting power, and Dr. James I. Healy, Dr. Maha Katabi, and Dr. Michael F. Powell, the managing members of SM X, may be deemed to have shared power to vote these shares. Such individuals disclaim beneficial ownership of such shares except to the extent of their pecuniary interest therein.
  3. The price reported in Column 4 is a weighted average price. These shares were acquired in multiple transactions at prices ranging from $70.66 to $71.50, inclusive. The reporting person undertakes to provide to Karuna Therapeutics, Inc., any security holder of Karuna Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the ranges set forth in this footnote (3) to this Form 4.
  4. The price reported in Column 4 is a weighted average price. These shares were acquired in multiple transactions at prices ranging from $72.30 to $73.27, inclusive. The reporting person undertakes to provide to Karuna Therapeutics, Inc., any security holder of Karuna Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the ranges set forth in this footnote (4) to this Form 4.
  5. The price reported in Column 4 is a weighted average price. These shares were acquired in multiple transactions at prices ranging from $73.30 to $74.00, inclusive. The reporting person undertakes to provide to Karuna Therapeutics, Inc., any security holder of Karuna Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the ranges set forth in this footnote (5) to this Form 4.